HAMBURG, Germany – Boston Scientific Corp. exercised its $325 million option to acquire remaining shares and full ownership of Millipede Inc. upon Millipede's recent successful completion of a first-in-human clinical study of its system treatment of severe mitral regurgitation. Boston Scientific had already invested $90 million in the privately held company in January. Read More
